Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT00310024 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

NIH

Sponsor class

Conditions

Refractory Multiple Myeloma
Stage I Multiple Myeloma
Stage II Multiple Myeloma
Stage III Multiple Myeloma

Interventions

DRUG: bortezomib
DRUG: vorinostat
OTHER: laboratory biomarker analysis
OTHER: pharmacological study

Sponsor

National Cancer Institute (NCI)